DarioHealth Corp. (DRIO) Stock

DarioHealth Corp. (DRIO) is a Healthcare stock trading at $7.47 (as of 2026-08-20), with a market capitalization of $73.40M and a trailing P/E of 0.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

DarioHealth Corp. is a digital therapeutics company offering technology-enabled programs and associated devices for health management across multiple conditions. Its offerings include metabolic, musculoskeletal, behavioral health, and chronic condition solutions, plus a care management platform and test-related consumables and monitoring devices for users in the U.S., Canada, the EU, Australia, and New Zealand.

Understand DarioHealth Corp.: how it makes money

DarioHealth Corp. delivers digital therapeutics for metabolic, musculoskeletal, behavioral health, and chronic condition management, and it also provides a care management platform plus device-specific disposable test strip cartridges and lancets, selling these solutions to customers through business-to-business and other healthcare channels.

The profit engine is recurring revenue tied to contracted annual recurring contracts and customer retention, supported by its proprietary care management platform (DarioEngage) and the availability of device-specific disposables (test strip cartridges and lancets).

Revenue by segment (latest quarter)
B2B$0.0B
DTC$0.0B

Business quality (Weak): Mixed: solid gross margin, but the latest-quarter operating margin is deeply negative, and reported revenue is effectively 0.0B, so cost discipline and converting pipeline into contracted recurring revenue are central to the story.

Valuation: At 1× earnings, DRIO trades 98% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • Recurring revenue base is directly tracked via Contracted Annual Recurring Revenue: The company discloses Contracted Annual Recurring Revenue of 0.03 USD_B, which highlights that its operating model emphasizes contracted recurring arrangements.
  • Retention metric is favorable in the provided data: Customer Renewal Rate is shown as 90.0 percent, suggesting renewals are a key strength to monitor in future quarters.
  • Platform and solution breadth span multiple condition areas: Its offerings include metabolic solutions, Dario Musculoskeletal, behavioral health, chronic condition management, and DarioEngage, plus device-specific disposables (test strip cartridges and lancets).

Bear case

  • Operating losses are large in the latest quarter: Operating margin for the latest quarter is -130.9 percent, indicating operating costs exceed operating gross profit by a wide margin.
  • Reported revenue is effectively zero in the provided quarter data: Revenue_b is listed as 0.0 for the period ended 2026-03-31, which can complicate assessing near-term scale using the provided figures.
  • Channel-specific contribution is unclear from the provided segment breakdown: The provided segment candidate values show Business-to-Consumer Revenues at 0.0, which raises the need to understand how much revenue is actually generated outside the Business-to-Business line.
Valuation — source: SEC EDGAR (first-party)
Price$7.47
Market Cap$73.40M
P/E Ratio0.6
EV / EBITDA-3.3
Price / Book1.33
Price / Sales3.50
FCF Yield-34.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$22.36M
Net Margin-186.6%
Return on Equity-64.8%
Debt / Equity0.66
Current Ratio2.31
Revenue Growth (YoY)-3.6%
EPS Growth (YoY)372.2%
FCF Growth (YoY)0.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.59 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Stock P/E0.6
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector-97.0%
vs Industry-98.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderNantahala Capital Management, LLC ($4.90M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOErez Raphael
Employees196
CountryUS
IPO Date2016-03-14

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Microbot Medical Inc. (MBOT)
  • Pulmonx Corporation (LUNG)
  • Sharps Technology, Inc. (STSS)
  • CVRx, Inc. (CVRX)
  • Sensus Healthcare, Inc. (SRTS)
  • Spectral AI, Inc. (MDAI)
  • Nephros, Inc. (NEPH)
  • Xtant Medical Holdings, Inc. (XTNT)
DRIO earnings history · DRIO institutional & insider holders · DRIO KPIs & operating metrics · DRIO financials · DRIO investor presentations & press releases · DRIO SEC filings · DRIO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.